DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Hypertension Screening and Treatment Program

Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Chlorthalidone (Drug); Furosemide (Drug)

Phase: N/A

Status: Completed

Sponsored by: Department of Veterans Affairs

Summary

Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.

Clinical Details

Official title: VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY)

Study design: Time Perspective: Prospective

Detailed description: Primary Hypothesis: A variety of clinical questions of major importance can be addressed using clinical data routinely obtained in the VA Hypertension Screening and Treatment Program. For example, treatment of mild hypertension reduces the risk of strokes and heart attacks. Secondary Hypothesis: Target organ damage occurs despite blood pressure control. Intervention: Chlorthalidone, furosemide, hydrochlorothiazide, metolazone, indapamide, amiloride, spironolactone, triamterene, atenolol, metoprolol, nadolol, pindolol, propranolol, timolol, acebutolol, penbutolol, clonidine, guanethidine, methydopa, prazosin, guanadrel, labetalol, reserpine, guanfacine, hydralazine, minoxidil, captopril, enalapril, lisinopril, diltiazem, nifedipine, verapamil, nicardipine, dyazide, maxzide, pargyline, terazosin, other anti-hypertensives. Primary Outcomes: Blood Pressure and Target Organ Damage Study Abstract: Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. This demonstration project provides for central collection of a standard set of clinical data for patients at some of the Hypertension Screening and Treatment Program clinics, thereby setting up a national data base on the treatment of hypertension. The primary objective of this project is to demonstrate the value of establishing this type of database. The database is being used to estimate the average annual cost of different antihypertensive regimens, to determine the cost-efficacy of different therapies and the least expensive effective therapy and to address some major unanswered clinical questions that require large populations and long-term patient care data. There are currently 13 medical centers participating.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Patients at Hypertension Screening and Treatment Program clinics

Locations and Contacts

Vamc - San Juan, Pr, San Juan, Puerto Rico

Vamc - Sepulveda, Sepulveda, California, United States

Vamc - Washington, Dc, Washington, District of Columbia, United States

Vamc - Miami, Miami, Florida, United States

Vamc - Indianapolis, Indianapolis, Indiana, United States

Vamc - Iowa City, Iowa City, Iowa, United States

Vamc - Jackson, Jackson, Mississippi, United States

Vamc - Dayton, Dayton, Ohio, United States

Vamc - Philadelphia, Philadelphia, Pennsylvania, United States

Vamc - Pittsburgh, Pittsburgh, Pennsylvania, United States

Vamc - Memphis, Memphis, Tennessee, United States

Vamc - Richmond, Richmond, Virginia, United States

Additional Information

Starting date: June 1989
Last updated: January 20, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017